Loading…
Shanghai-area CDMO/CRO providing custom pharmaceutical intermediate and API research and manufacturing services.
Shanghai-area CDMO/CRO providing custom pharmaceutical intermediate and API research and manufacturing services.
Sells a very large catalogue of ready-made chemical building blocks that drug researchers order like parts, so revenue follows the steady stream of discovery work and small repeat orders, not large single contracts. Custom synthesis and manufacturing for drug developers are a smaller add-on.
In one line: A small Chinese pharma-intermediate CDMO.
Moat: narrow (process know-how, switching costs). Chemistry know-how and qualified supply relationships built into a drug's regulatory filing are sticky.
Headquarters: Shanghai, China · Employees: 734
Size Bide Pharmatech (688073.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $912M, the 2488th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥66.93 on 6 Nov 2026.
Performance Over six months the shares gained 5.4%, against -14.9% for the median peer and -16.4% for the China market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 9.9% over the last twelve months (peer median +1.3%); the operating margin is 18.8% (peer median 2.6%).
Valuation It trades at 27.5× forward earnings against a peer median of 27.6× (5th cheapest of 9).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.3 points above its cost of capital (11.5% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.40B | CN¥1.32B | CN¥1.10B | CN¥1.09B | CN¥830M |
| Revenue growth | — | +20% | +1% | +31% | — |
| Gross profit | CN¥691M | CN¥566M | CN¥430M | CN¥414M | CN¥352M |
| EBITDA | n/a | CN¥227M | CN¥154M | CN¥140M | CN¥170M |
| Net income | CN¥196M | CN¥152M | CN¥117M | CN¥110M | CN¥146M |
| Free cash flow | CN¥191M | CN¥12.9M | CN¥74.8M | -CN¥118M | -CN¥8.54M |
| Capital expenditure | CN¥21.6M | CN¥24.3M | CN¥88.3M | CN¥61.1M | CN¥38.4M |
| Total debt | CN¥130M | CN¥141M | CN¥82.4M | CN¥57.3M | CN¥40.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bide Pharmatech 688073.SS | $912M | +5% | +10% | 19% | 27.5× | 16.7% |
| Wuxi Apptec 2359.HK | $66.3B | +40% | +38% | 44% | 20.4× | 8.7% |
| Porton Pharma Solutions 300363.SZ | $1.92B | +14% | +6% | -2% | n/a | 5.3% |
| Asymchem Laboratories (Tianjin) 002821.SZ | $8.07B | +23% | +18% | 17% | 41.4× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688073.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.5% | -7.3% | 8th highest of 20 |
| 6-month return | +5.4% | -14.9% | 3rd highest of 20 |
| Distance from 52-week high | -24.7% | -35.5% | 6th highest of 21 |
| Revenue growth (TTM) | +9.9% | +1.3% | 6th highest of 19 |
| Operating margin | 18.8% | 2.6% | 2nd highest of 19 |
| Forward P/E | 27.5× | 27.6× | 5th cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | 16.7% | 5.2% | 2nd most demanding of 9 |
| Growth delivered (Del g) | +27.7% | +6.7% | highest of 9 |
| Hurdle (Req g minus delivered) | -11.0 pp | -4.9 pp | 3rd least demanding of 9 |
| ROIC minus cost of capital | +7.3 pp | -2.8 pp | 3rd highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bide Pharmatech 688073.SS | China | $912M | +5% | +10% | 19% | 27.5× | 16.7% | +27.7% |
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $909M | -33% | -14% | -29% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | n/a | -1.2% | -39.5% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | n/a | 16.2% | -0.2% |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | n/a | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 41.1× | 33.2% | +4.2% |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $894M | -8% | -1% | -2% | 30.6× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $893M | -27% | +1% | 0% | n/a | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 24.5× | 16.2% | +27.3% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $892M | +19% | +13% | 18% | n/a | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $887M | -32% | n/a | n/a | n/a | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 33.8× | n/a | n/a |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Aktis Oncology AKTS | United States | $880M | -15% | +337% | -1,150% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | n/a | -6.8% | -0.7% |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $874M | -30% | +9% | 12% | 5.8× | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $874M | -2% | +2% | 9% | 41.4× | 2.5% | +12.4% |
| Hygeia Healthcare 6078.HK | Hong Kong | $861M | -7% | +2% | 14% | 11.0× | 4.8% | +22.5% |
| Procter & Gamble Health PGHL.NS | India | $971M | +4% | +13% | 31% | 24.7× | 5.5% | +9.3% |